LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
TOKYO and RAHWAY, N.J., Sept 17, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSDoutside of the United States and … Read More